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Noonan-like syndrome with loose anagen hair (NS/LAH; OMIM #607721) has been recently related to the invariant
c.4A >G missense change in SHOC2. It is characterized by features reminiscent of Noonan syndrome. Ectodermal
involvement, short stature associated to growth hormone (GH) deficiency (GHD), and cognitive deficits are
common features. We compare in two patients with molecularly confirmed NS/LAH diagnosis, the clinical
phenotype and pathogenetic mechanism underlying short stature. In particular, while both the patients exhibited a
severe short stature, GH/IGFI axis functional evaluation revealed a different pathogenetic alteration, suggesting in
one patient an upstream alteration (typical GHD) and in the other one a peripheral GH insensitivity.
Since only a few cases of NS/LAH associated to SHOC2 mutations have been so far described, the complex
phenotype of the syndrome and the exact mechanism impairing GH/IGFI axis still remain to be elucidated and
studies on larger cohort of subjects are needed to better delineate this syndrome.
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“Noonan-like syndrome with loose anagen hair” (NS/
LAH OMIM60772) is a syndrome first described in
2003, characterized by features reminiscent of NS and a
unique pattern of ectodermal abnormalities [1]. Recently,
Cordeddu et al. discovered that an invariant mutation in
SHOC2, c.4A >G, predicting the p.Ser2Gly change in
the encoded protein, underlies this condition. SHOC2
encodes a scaffold protein that positively modulates
RAS-MAPK signal flow. The mutation was documented
to promote N-myristoylation of the protein, and to drive
aberrant targeting of SHOC2 to the plasma membrane
and increased ERK activation in a cell context-specific
fashion [2]. The phenotype of these subjects is character-
ized by facial features reminiscent of NS, short stature,
cognitive deficits, distinctive hyperactive behavior, con-
genital hearth disease, and easily pluckable, sparse, thin,
slow-growing hair in the anagen phase but lacking an
inner and outer root sheaths.* Correspondence: salerno@unina.it
Department of Pediatrics, “Federico II” University of Naples, Naples, Italy
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reproduction in any medium, provided the orShort stature is one of the most common features
observed in NS as well as in other disorders associated
to RAS-MAPK dysregulation. It is well known that the
RAS-MAPK transduction pathway plays a key role in
growth hormone (GH) signaling [3]. However, the exact
mechanism of impaired GH-IGF1-axis in patients with
aberrant RAS-MAPK signaling is still controversial. An
altered response of GH to stimulation tests has been
reported in some children [4,5], whereas other authors
have reported normal GH secretion with low IGF1 levels
suggesting a peripheral GH insensitivity (GHI) [6,7].
GHI is a condition characterized by the peripheral resist-
ance to GH action [8-10]. Transduction of the signals
elicited by GHR is mediated by the JAK/STAT pathway.
Tyrosine phosphorylation of JAK2 and STAT5 plays a
crucial role in such a process, which eventually results in
gene transcription [11-13]. The most common form of
GHI is due to GHR mutations; other forms are caused
by abnormalities in the signaling cascade downstream to
GHR and, in particular, involving STAT5b [9,11]. In sub-
jects with STAT5b defects short stature is associatedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ment [8,14,15].
In children with NS/LAH short stature is mainly asso-
ciated to proven GH deficiency (GHD) [2].
So far, only a few patients with NS/LAH have been
described and the phenotype of the syndrome still
remains to be delineated. We recently reported on a
patient affected with this syndrome, who exhibited a
GHI [16]. Herein, we compare the clinical phenotype
and the pathogenetic mechanism underlying short sta-
ture and abnormal GH/IGFI axis between the already
described patient and a further affected child with the
same mutation of the SHOC2 gene.
Subjects
Patient 1
The patient was born preterm (34 weeks of gestation)
with a pregnancy complicated by polyhydramnios. Parents
were not consanguineous. Birth weight was 2.450 kg
(75th centile), length was 45 cm (25th-50th centile). She
was referred to our attention at the age of 7 years for
short stature. Physical examination revealed macroce-
phaly, high forehead, epicanthic folds, palpebral ptosis,
hyperthelorism, high and narrow palate, pterigium colli,
pectus excavatum with widely spaced nipples, deep pal-
mar and plantar creases (Figure 1a). She had severe
growth delay: weight was 13 kg (−4.4 SDS) and height
was 97 cm (−5.7 SDS), with impaired linear growth ve-
locity (3 cm/year). Bone age was delayed by three years.
Karyotype was normal (46, XX). Neurological evaluation
revealed a mild psychomotor delay (IQ: 52) with impair-
ment of verbal and language abilities. Cerebral MRI
showed hypoplastic corpus callosum. Based on these fea-
tures, NS disease genes were screened (PTPN11, KRAS,
SOS1, MEK1, BRAF) but mutation analysis failed to
reveal any causative mutation.
Biochemical evaluation of GH-IGF1 axis, performed to
investigate the cause underlying short stature, revealedFigure 1 Patient 1 at 9 years of age (a) and patient 2 at 13 years (b) ilow serum levels of IGF1 (27 ng/ml, nv 60–350) and
normal GH peak after arginine stimulation (16 ng/ml),
thus excluding a GHD [17] and suggesting a condition
of mild GH insensitivity (GHI). An IGFI generation test
confirmed the condition of GHI, revealing only a mild
increase of IGFI levels (55 ng/ml) after stimulation with
exogenous GH with respect to basal values (30 ng/ml).
Moreover, the peak value obtained was still below the
mean value for age (60–350 ng/ml). GHI was not related
to mutations in GH receptor in that molecular analysis
of GHR gene was normal. Moreover, intracellular sig-
nalling elicited by GHR perturbation, evaluated through
the analysis of GH-induced tyrosine phosphorylation of
Signal Transducers and Activators of Transcription
(STAT)5, was normal.
The patient underwent a therapeutic trial with recom-
binant human (rh) GH at a mean dose of 45 μg/kg/die.
However, no significant improvement in linear growth
was observed. Nevertheless, an arrest of growth velocity
was observed when GH treatment was stopped. Thus,
GH was re-started in order to normalize growth velocity
(Figure 2a).
Over time, several ectodermal abnormalities became
evident, including nail dystrophy, dry, fine textured,
sparse hair, which were easily pulled from the scalp, and
dry, hairless, darkly pigmented skin. Such a distinctive
association prompted SHOC2 mutation analysis which
confirmed the presence of the disease-causing mutation
(c.4A >G, p.Ser2Gly), thus confirming diagnosis of NS/
LAH. At 9 years, she suddenly presented with complex
motor and vocal tics characterized by repetitive stereo-
typed movements predominantly involving facial and
shoulder muscles and repetitive sounds, which persisted
for more than 1 year. Major causes of secondary tics dis-
orders in childhood were excluded, including occurrence
of neurodegenerative disease, central nervous system
infections, pediatric autoimmune neuropsychiatric dis-
order associated with streptococcal infection (PANDAS)n a frontal view.
Figure 2 Longitudinal growth curve of the 2 patients before and after (arrow) growth hormone (GH) therapy.
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sented with a generalized convulsive event. Electroence-
phalography revealed the presence of focal abnormalities
in both parietal and occipital areas, whereas MRI con-
firmed the previous finding of corpus callosum hypopla-
sia and showed diffuse reduction in the white matter. She
was then treated with carbamazepine with a good control
on seizures but without any effect on tic disorders. She is
now 13 years old. Despite a 6-years GH treatment, she still
has a severe short stature (height −5 SDS) (Figure 2a), and
IGF1 levels well below the normal range (93.5 ng/ml; nv
180–780) [16].
Patient 2
The patient was born at term (40 weeks of gestation)
after a normal pregnancy and caesarian delivery from
not consanguineous parents. Birth weight was 3.75 kg
(50-75th centile), length was 48 cm (10-25th centile) and
head circumference 37 cm (>90°). At birth, a large atrial
septal defect with pulmonary hyperflow was detected.
She was referred to our Department at the age of
9 years because of short stature. Physical examinationrevealed macrocephaly, high forehead, epicanthic folds,
low-set and posterior angulated left ear, hyperthelorism,
short neck with redundant skin, pectus excavatum, fine,
dry, fine textured, sparse hair, darkly pigmented skin
with cafe au lait spots, tuberous angioma in the left
hypochondrium, hyperextensible joints and mild scoliosis
(Figure 1b). She had a severe growth delay: weight was
16.5 kg (−3.72 SDS) and height was 113.5 cm (−3.21
SDS). Bone age was delayed by two years. Karyotype was
normal (46, XX). She had only a mild psychomotor delay
(IQ 65) and behavioral problems. Cerebral MRI showed
type I Chiari malformation.
The biochemical evaluation showed a subclinical
hypothyroidism (SH) on the basis of a mild increase of
TSH levels in the absence of thyroid autoantibodies
which normalized over time, associated with normal
values of circulating hormones, thus not requiring re-
placement therapy [19-22]. The presence of APA was
also excluded as an autoimmune cause of short stature
[23]. Biochemical evaluation of GH-IGF1 axis, per-
formed to investigate the cause of the short stature,
revealed abnormal GH peak after clonidine stimulation
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serum levels of IGF1 at the lower limit of normal range
(70.4 ng/ml ), indicative of a condition of partial GH
deficiency She was then started on recombinant human
(rh) GH at a mean dose of 40 μg/kg/die, with only a
blunted response to treatment (Figure 2b). At the age
of 17 years she stopped the therapy (Figure 2b).
Later on during the follow-up, the girl showed an
improvement in her psychomotor development and be-
havior skills.
Since at the age of 14 years no signs of pubertal deve-
lopment were evident, a LHRH test was performed re-
vealing normal activation of the gonadotropic axis (peakTable 1 Phenotipic features of Noonan-like syndrome
with loose anagen hair in our two patients
Patient 1 Patient 2
Skin and hair
Dark skin + +
Hyperkeratosis - -
Dermatitis/eczema - -
Sparse/absent scalp hair + +
Curly hair - -





Epicanthal folds + +
Nose
Depressed nasal bridge - -
Anteverted nostrils - -
Oral cavity
High-arched palate - +
Ears
Apparently low-set ears + -
Retroverted ears Neck + -
Neck
Broad, short, webbed + +
Chest




Dilated ventricles - -
Mental retardation - +
Tic - +
Growth and development
Short stature + +
Lymphatic dysplasias + -of LH 14.4 mU/mL; peak of FSH 21.7 mU/mL). Never-
theless, no pubertal progression was observed in the fol-
lowing years and at the age of 16 years she was started
on hormonal replacement.
The complex clinical phenotype prompted to the
clinical diagnosis of NS/LAH and molecular analysis of
SHOC2 revealed the presence of the disease-causing
mutation (c.4A >G, p.Ser2Gly).
In Table 1 a comparison of the two phenotypes has
been reported.
Discussion
We reported on two patients with molecularly con-
firmed diagnosis of NS/LAH exhibiting different features
of the disease and different pathogenetic mechanisms
underlying the impairment of GH-IGFI axis resulting in
short stature.
Both patients had the similar facial dysmorphism,
skeletal abnormalities, ectodermal abnormalities and
psychomotor delay, even though these features were
more pronounced in the patient 1. Patient 1 also had
epilepsy and atypical neurologic signs such as chronic
vocal and motor tics, never previously reported in
patients with SHOC2 mutations or in any other condi-
tion due to RAS-MAPK dysregulation. The precise
etiology of chronic tics in childhood often remains
elusive. However, abnormalities in the dopamine path-
ways have been supposed as possible mechanism under-
lying neurotransmitter alterations [24]. Recent evidence
suggests that RAS-MAPK pathway is involved in signal
transduction that follows dopamine receptors triggering
[25]. Thus, one could speculate that in our patient dysre-
gulation of RAS-MAPK due to dysregulated SHOC2
function might be related to tics disorders through an
alteration of dopamine-signaling. In keeping with this,
studies on Gilles de la Tourette syndrome (GTS), one of
the most frequent causes of chronic tics in infancy, also
indicate a potential role of immune activation, mediated
by RAS-MAPK stimulating cytokines, in the pathoge-
nesis of tics and other hyperkinetic disorders [26].
As for developmental and behavioral features, again
patient 1exhibited persistent alterations during adoles-
cence, differently from patient 2 who only had a mild
delay improving over time.
Both patients had severe short stature, even though
GH/IGFI axis was differently altered. In fact, in the
patient 1 the evaluation of GH-IGFI axis revealed a
condition of GHI, whereas in patient 2 a partial GH
deficiency was found. So far, GHD represents the most
common cause of short stature in NS/LAH syndrome.
Differently, GHI has never been described in NS/LAH
subjects. In our second patient, molecular analysis of
GHR and GH-induced phosphorylation of STAT5 were
normal, thus excluding the most common receptorial or
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Since both patients with GHD and with GHI share the
same mutation, it seems unlikely that this mutation cause
GHI per se. However, it is conceivable that SHOC2 mu-
tation alters GHR signaling through dysregulation of
RAS-MAPK pathway, thus contributing to cause GHI.
In keeping with this, GH replacement therapy was un-
successful in the patient 1. The observation that also in
the patient 2, in spite of GHD the GH replacement
therapy was not fully successful indicates that SHOC2
has multiple roles in either central or peripheral control
of GH-IGFI axis functionality.
The clinical heterogeneity in our 2 patients carrying
the same mutation, is not surprising as other monogenic
diseases have been already shown to have a different
phenotype despite the same causing mutation [27-30].
For most of these conditions, molecular basis of this he-
terogeneity are not well delineated. Disease modifying
genes, variation in environmental exposures, as well as
system dynamics may come into play in modulating cli-
nical expression of the disease [31].
Conclusion
In conclusion, we reported on two patients with
NS/LAH due to the invariant c.4A >G mutation in
SHOC2, with a different phenotype of the disease and
severe short stature related to different mechanisms
impairing GH-IGFI axis. Since only a few cases of the
NS/LAH have so far been described, studies on larger
cohort of subjects are needed to better delineate the
phenotypic heterogeneity and to better define the patho-
genetic mechanism underlying short stature in these
patients.
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